Clinical trials: Duloxetine
Urinary Stress Incontinence
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
- Trial name
- NCT00190606
- Testing
- Duloxetine, Pelvic Floor Muscle Training (PFMT), Imitation PFMT
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuralgia, Diabetic Neuropathies
Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD).
- Conditions
- Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
- Trial name
- NCT00507936
- Testing
- ABT-894, Duloxetine
- Where
- 49 sites in United States, Canada and 5 more
- Volunteers
- 280 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Major Depressive Disorder
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
- Trial name
- NCT00854100
- Testing
- Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
- Where
- 41 sites in United States
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Urinary Incontinence, Stress
Efficacy and Safety Stress Urinary Incontinence Study
Study F1J-MC-SBBT will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.
- Trial name
- NCT00475358
- Testing
- Duloxetine
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
To assess the effectiveness of duloxetine administered once daily in patients with Major Depressive Disorder in a practice based setting
- Trial name
- LEAPS (NCT00479726)
- Testing
- duloxetine hydrochloride
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Eli Lilly and Company
Anxiety Disorders
Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder
This is a clinical trial assessing duloxetine compared with placebo in patients who have generalized anxiety disorder.
- Trial name
- NCT00122824
- Testing
- duloxetine hydrochloride
- Where
- 7 sites in United States, Finland and 5 more
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Pain Management, Cancer Pain
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
The purpose of this study is to compare efficacy of pain treatment with ITDD to efficacy of pain treatment with CMM in patients with pancreatic cancer pain.
- Trial name
- NCT02578459
- Testing
- Intrathecal Drug Delivery System, Conventional Medical Management
- Where
- United States
- Sponsor
- Flowonix Medical
Anxiety Disorders
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
This study will examine duloxetine compared with placebo and an active comparator in the treatment of generalized anxiety disorder.
- Trial name
- NCT00122850
- Testing
- Duloxetine, venlafaxine
- Where
- 19 sites in United States
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathies
A Study for the Treatment of Diabetic Peripheral Neuropathic Pain
The purpose of the study is to determine if duloxetine can help patients with painful diabetic neuropathy.
- Trial name
- NCT00552175
- Testing
- Duloxetine hydrochloride - 40 mg, Duloxetine hydrochloride - 60 mg
- Where
- 25 sites in Japan
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Fibromyalgia
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia
The objective of this study is to evaluate the safety, tolerability and efficacy of milnacipran in patients with an inadequate response to duloxetine for the treatment of fibromyalgia.
- Trial name
- NCT01077375
- Testing
- Milnacipran
- Where
- 26 sites in United States
- Volunteers
- 107 people
- Sponsor
- Forest Laboratories
Diabetic Neuropathy, Painful
A Study in Participants With Diabetic Peripheral Neuropathic Pain in China
The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as measured by the weekly mean of the daily pain…
- Trial name
- NCT01179672
- Testing
- Duloxetine
- Where
- 15 sites in China
- Volunteers
- 405 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042575
- Testing
- Duloxetine
- Where
- 9 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder…
- Trial name
- NCT00635219
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 766 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Dose-finding Study With Lu AA24530 in Major Depressive Disorder
The primary purpose of this study is to assess the efficacy in treating patients with Major Depressive Disorder of one or more doses of Lu AA24530 relative to placebo
- Trial name
- NCT00599911
- Testing
- Lu AA24530, Duloxetine
- Where
- 72 sites in Australia, Austria and 15 more
- Volunteers
- 652 people
- Sponsor
- H. Lundbeck A/S
Osteoarthritis of the Knee
An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)
The purpose of this study is to assess the safety and efficacy of duloxetine in participants with osteoarthritis and knee pain. The study will last for 1 year.
- Trial name
- NCT02335346
- Testing
- Duloxetine
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Eli Lilly and Company
Bioequivalence
Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions
This Study will investigate the bioavailability in fasting subjects of 1 capsule formulation containing Duloxetine 60 mg. The Study will be performed at a single site with 36 subjects.Participants will take 1 capsule of the test…
- Trial name
- NCT04751318
- Testing
- Duloxetine 60mg Test Drug Enteric Coated Granules, Duloxetine 60mg Reference Product Enteric Coated Granules
- Where
- Chile
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Laboratorios Andromaco S.A.
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- DIAMOND (NCT00321490)
- Testing
- Quetiapine fumarate, Duloxetine
- Where
- 34 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Fibromyalgia
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.
- Trial name
- NCT00190866
- Testing
- Duloxetine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company